Czech
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Strana 1 z 84 Výsledek
The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
The aim of this study was to evaluate the efficacy and safety of a new low-concentration estriol formulation (0.005% estriol vaginal gel), providing an ultra low dose of estriol per application (50 μg), for the local treatment of postmenopausal vaginal atrophy.
METHODS
Postmenopausal women
Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
The aim of the study was to confirm the superior efficacy of estriol containing pessaries compared to placebo in the treatment of vaginal atrophy.
METHODS
In a prospective, multicenter, randomized, placebo-controlled, double-blind study, 436 postmenopausal women with vaginal atrophy
[Postmenopausal vaginal atrophy and topical therapy with an estriol-based ointment (Colpogyn): authors' experience].
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
The paper reports the results of a study to assess the efficacy of an estriol-based cream (Colpogyn) in the topical treatment of postmenopausal vaginal atrophy. 0.5 mg of estriol were applied daily for 10 consecutive days and three times a week for 2 weeks. Trophism of vaginal epithelium appeared to
Efficacy of vaginal use of topical estriol in postmenopausal women with urogenital atrophy.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
This study evaluates the effect of intravaginal estriol on urogenital atrophy, Pap smear parameters, colposcopy parameters and discomfort during gynecological examination.
METHODS
31 postmenopausal women who had not used hormone therapy in the previous six months were studied. All women
Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Vulvo-vaginal atrophy (VVA) is a chronic condition affecting many postmenopausal women. Local estrogen treatment is recommended. Evaluating efficacy and safety of long-term VVA treatment with ultra-low-dose estriol gel, 120 postmenopausal VVA women were enrolled in a prospective study. They received
Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND
Atrophic vaginitis is a common condition. This study compared the usefulness of estradiol vaginal tablets (EVT) and estriol vagitories (EV) in treatment of atrophic vaginitis.
METHODS
Ninety-six postmenopausal women with symptoms of atrophic vaginitis were treated for 24 weeks with either
The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
To evaluate the efficacy and safety of estriol for the treatment of vulvovaginal atrophy in postmenopausal women.
METHODS
A systematic literature review was performed. We searched the following electronic databases: Medline, Cochrane, Embase, Lilacs, CINHAL and Google Scholar. The studies
Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
The aim of this study was to demonstrate the efficacy of an ultra-low-dose vaginal estriol 0.03 mg in combination with viable Lactobacillus acidophilus KS400 (Gynoflor(®) vaginal tablets) in the short-term therapy and to investigate the long-term maintenance dose in the treatment of
Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
To determine if the efficacy of continuous low dose estradiol released from a vaginal ring is equivalent to estriol vaginal cream regarding improvement of the patient's subjective feeling of vaginal dryness and to determine if there is a preference for either of the two study
Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
In recent years, a vast quantity of clinical data has been accumulated on the pathophysiology of symptomatic vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM) in peri- and postmenopausal women and on the treatment options for these conditions. Guidelines from several societies
Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Phase I pharmacokinetic (PK) study assessed circulating estrogens in breast cancer (BC) patients on a non-steroidal aromatase inhibitor (NSAI) with vaginal atrophy using vaginal ultra-low-dose 0.03 mg estriol (E3) and Lactobacillus combination vaginal tablets (Gynoflor(®)). 16 women on NSAI with
Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
The aim of the study was to evaluate efficacy of fractional CO2 vaginal laser treatment (Laser, L) and compare it to local estrogen therapy (Estriol, E) and the combination of both treatments (Laser + Estriol, LE) in the treatment of vulvovaginal atrophy (VVA).
METHODS
A total of 45
A comparative multicenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE
Our purpose was to study the efficacy, safety, and acceptability of a new estradiol-releasing (6.5 to 9.5 micrograms per 24 hours) silicone rubber vaginal ring compared with Ovesterin 0.5 mg estriol vaginal pessaries.
METHODS
Gynecologic clinical status, vaginal pH, cytologic
[DEGENERATION AND NECROSIS OF THE LIVER AND KIDNEY IN RATS AFTER THE ADMINISTRATION OF HIGH DOSES OF 17-BETA-ESTRADIOL AND ESTRIOL].
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Nejúplnější databáze léčivých bylin podložená vědou
- Funguje v 55 jazycích
- Bylinné léky podporované vědou
- Rozpoznávání bylin podle obrázku
- Interaktivní mapa GPS - označte byliny na místě (již brzy)
- Přečtěte si vědecké publikace související s vaším hledáním
- Hledejte léčivé byliny podle jejich účinků
- Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty
Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu
